Current status of herbal medicines in chronic liver disease therapy: The biological effects, molecular targets and future prospects

International Journal of Molecular Sciences

Volumn 16, Issue 12, 2015, Pages 28705-28745

  Hong, Ming ^a   Li, Sha ^a   Tan, Hor Yue ^a   Wang, Ning ^a   Tsao, Sai Wah ^b   Feng, Yibin ^a  

^a THE UNIVERSITY OF HONG KONG   (Hong Kong)

^b UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Chinese medicine herbal formulae; Chronic liver disease; Herbal medicines; Molecular targets

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BAICALIN; BERBERINE; BIEJIA RUANGAN; BILIRUBIN; CHINESE DRUG; COPTIS CHINENSIS EXTRACT; CRYPTOTANSHINONE; FUZHENG HUAYU; GALLIC ACID; GAMMA GLUTAMYLTRANSFERASE; GLYCYRRHIZIC ACID; HERBACEOUS AGENT; HUANGLIAN JIEDU DECOCTION; LIVER PROTECTIVE AGENT; OXYMATRINE; PHYLLANTHUS NIRURI EXTRACT; PUERARIN; SAIKOSAPONIN D; SCHISANDRA CHINENSIS EXTRACT; SCHIZANDRIN B; SCUTELLARIA BAICALENSIS EXTRACT; SILIBININ; SILYMARIN; SUPEROXIDE DISMUTASE; UNCLASSIFIED DRUG; UNINDEXED DRUG; WOGONIN; XIAO CHAI HU TANG; PLANT MEDICINAL PRODUCT;

AUTOIMMUNE HEPATITIS; BUPLEURUM CHINENSE; CHINESE MEDICINE; CHRONIC HEPATITIS; CHRONIC HEPATITIS B; CHRONIC LIVER DISEASE; CLINICAL TRIAL (TOPIC); DOWN REGULATION; FATTY LIVER; HERBAL MEDICINE; HUMAN; IMMUNOMODULATION; LIVER CANCER; LIVER CIRRHOSIS; LIVER PROTECTION; META ANALYSIS (TOPIC); MULTICENTER STUDY (TOPIC); NONHUMAN; PERIPLOCA; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHYTOCHEMISTRY; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW; UPREGULATION; ANIMAL; CHEMISTRY; CHRONIC DISEASE; LIVER DISEASES; MEDICINAL CHEMISTRY; METABOLISM; PATHOLOGY; PROCEDURES; RESEARCH; TREATMENT OUTCOME;

ANIMALS; CHEMISTRY, PHARMACEUTICAL; CHRONIC DISEASE; DRUGS, CHINESE HERBAL; HERBAL MEDICINE; HUMANS; LIVER DISEASES; MEDICINE, CHINESE TRADITIONAL; PHYTOCHEMICALS; RESEARCH; TREATMENT OUTCOME;

EID: 84949423234     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms161226126     Document Type: Review

References (243)

1. Wood, N.J. Liver: Nonobese individuals in the developing world are at risk of nonalcoholic fatty liver and liver disease. Nat. Rev. Gastroenterol. Hepatol. 2010, 7, 357. [CrossRef] [PubMed]
2. Vong, S.; Bell, B.P. Chronic liver disease mortality in the united states, 1990–1998. Hepatology 2004, 39, 476–483. [CrossRef] [PubMed]
3. Lazerow, S.K.; Abdi, M.S.; Lewis, J.H. Drug-induced liver disease 2004. Curr. Opin. Gastroenterol. 2005, 21, 283–292. [CrossRef] [PubMed]
4. Baig, N.A.; Herrine, S.K.; Rubin, R. Liver disease and diabetes mellitus. Clin. Lab. Med. 2001, 21, 193–207. [PubMed]
5. Orman, E.S.; Odena, G.; Bataller, R. Alcoholic liver disease: Pathogenesis, management, and novel targets for therapy. J. Gastroenterol. Hepatol. 2013, 28, 77–84. [CrossRef] [PubMed]
6. Wang, B.E. Treatment of chronic liver diseases with traditional chinese medicine. J. Gastroenterol. Hepatol. 2000, 15, E67–E70. [CrossRef] [PubMed]
7. Dhiman, A.; Nanda, A.; Ahmad, S. A recent update in research on the antihepatotoxic potential of medicinal plants. J. Chin. Integr. Med. 2012, 10, 117–127. [CrossRef]
8. Del Prete, A.; Scalera, A.; Iadevaia, M.D.; Miranda, A.; Zulli, C.; Gaeta, L.; Tuccillo, C.; Federico, A.; Loguercio, C. Herbal products: Benefits, limits, and applications in chronic liver disease. Evid. Based Complement. Altern. Med. eCAM 2012, 2012, 837939. [CrossRef] [PubMed]
9. Ma, X.; Wang, J.; He, X.; Zhao, Y.; Wang, J.; Zhang, P.; Zhu, Y.; Zhong, L.; Zheng, Q.; Xiao, X. Large dosage of chishao in formulae for cholestatic hepatitis: A systematic review and meta-analysis. Evid. Based Complement. Altern. Med. eCAM 2014, 2014, 328152. [CrossRef] [PubMed]
10. Dunkelberg, J.C.; Berkley, E.M.; Thiel, K.W.; Leslie, K.K. Hepatitis b and c in pregnancy: A review and recommendations for care. J. Perinatol. Off. J. Calif. Perinat. Assoc. 2014, 34, 882–891. [CrossRef] [PubMed]
11. Damgaard Sandahl, T. Alcoholic hepatitis. Dan. Med. J. 2014, 61, B4755. [PubMed]
12. Ghabril, M.; Chalasani, N.; Bjornsson, E. Drug-induced liver injury: A clinical update. Curr. Opin. Gastroenterol. 2010, 26, 222–226. [CrossRef] [PubMed]
13. Krawitt, E.L. Clinical features and management of autoimmune hepatitis. World J. Gastroenterol. WJG 2008, 14, 3301–3305. [CrossRef] [PubMed]
14. Sanchez-Pobre, P.; Gonzalez, C.; Paz, E.; Colina, F.; Castellano, G.; Munoz-Yague, T.; Rodriguez, S.; Yela, C.; Alvarez, V.; Solis-Herruzo, J. Chronic hepatitis c and autoimmune cholangitis: A case study and literature review. Dig. Dis. Sci. 2002, 47, 1224–1229. [CrossRef] [PubMed]
15. Zhu, H.; Bodenheimer, H.C., Jr.; Clain, D.J.; Min, A.D.; Theise, N.D. Hepatic lipogranulomas in patients with chronic liver disease: Association with hepatitis c and fatty liver disease. World J. Gastroenterol. WJG 2010, 16, 5065–5069. [CrossRef] [PubMed]
16. Bartneck, M.; Warzecha, K.T.; Tacke, F. Therapeutic targeting of liver inflammation and fibrosis by nanomedicine. Hepatobil. Surg. Nutr. 2014, 3, 364–376.
17. Lee, U.E.; Friedman, S.L. Mechanisms of hepatic fibrogenesis. Best Pract. Res. Clin. Gastroenterol. 2011, 25, 195–206. [CrossRef] [PubMed]
18. Tariq, Z.; Green, C.J.; Hodson, L. Are oxidative stress mechanisms the common denominator in the progression from hepatic steatosis towards non-alcoholic steatohepatitis (nash)? Liv. Int. Off. J. Int. Assoc. Study Liv. 2014, 34, e180–e190. [CrossRef] [PubMed]
19. Lotersztajn, S.; Julien, B.; Teixeira-Clerc, F.; Grenard, P.; Mallat, A. Hepatic fibrosis: Molecular mechanisms and drug targets. Annu. Rev. Pharmacol. Toxicol. 2005, 45, 605–628. [CrossRef] [PubMed]
20. Arenas, V.J.J.; Nieto, G.M.; Romero, D.R.; Tortajada, G.B.; Faus, F.V. Review of enteral drugs administration for viral diseases: Hiv, hbv and hcv. Farm. Hosp. Org. Off. Exp. Cient. Soc. Esp. Farm. Hosp. 2013, 37, 412–418.
21. Babineaux, M.J.; Anand, B.S. General aspects of the treatment of alcoholic hepatitis. World J. Hepatol. 2011, 3, 125–129. [CrossRef] [PubMed]
22. Aguilar-Najera, O.; Velasco-Zamora, J.A.; Torre, A. Overlap syndromes of autoimmune hepatitis: Diagnosis and treatment. Rev. Gastroenterol. Mex. 2015, 80, 150–159. [CrossRef] [PubMed]
23. Kumada, H. Long-term treatment of chronic hepatitis c with glycyrrhizin [stronger neo-minophagen c (snmc)] for preventing liver cirrhosis and hepatocellular carcinoma. Oncology 2002, 62, 94–100. [CrossRef] [PubMed]
24. Matsumoto, Y.; Matsuura, T.; Aoyagi, H.; Matsuda, M.; Hmwe, S.S.; Date, T.; Watanabe, N.; Watashi, K.; Suzuki, R.; Ichinose, S., et al. Antiviral activity of glycyrrhizin against hepatitis c virus in vitro. PLoS ONE 2013, 8, e68992. [CrossRef] [PubMed]
25. Fujisawa, Y.; Sakamoto, M.; Matsushita, M.; Fujita, T.; Nishioka, K. Glycyrrhizin inhibits the lytic pathway of complement-possible mechanism of its anti-inflammatory effect on liver cells in viral hepatitis. Microbiol. Immunol. 2000, 44, 799–804. [CrossRef] [PubMed]
26. Abe, M.; Akbar, F.; Hasebe, A.; Horiike, N.; Onji, M. Glycyrrhizin enhances interleukin-10 production by liver dendritic cells in mice with hepatitis. J. Gastroenterol. 2003, 38, 962–967. [CrossRef] [PubMed]
27. Matsuo, K.; Takenaka, K.; Shimomura, H.; Fujii, N.; Shinagawa, K.; Kiura, K.; Harada, M. Lamivudine and glycyrrhizin for treatment of chemotherapy-induced hepatitis b virus (hbv) hepatitis in a chronic hbv carrier with non-hodgkin lymphoma. Leuk. Lymphoma 2001, 41, 191–195. [CrossRef] [PubMed]
28. Van Rossum, T.G.; Vulto, A.G.; Hop, W.C., Schalm, S.W. Glycyrrhizin-induced reduction of alt in european patients with chronic hepatitis c. Am. J. Gastroenterol. 2001, 96, 2432–2437. [CrossRef]
29. Kidd, P.; Head, K. A review of the bioavailability and clinical efficacy of milk thistle phytosome: A silybin-phosphatidylcholine complex (siliphos). Altern. Med. Rev. J. Clin. Ther. 2005, 10, 193–203.
30. Bonifaz, V.; Shan, Y.; Lambrecht, R.W.; Donohue, S.E.; Moschenross, D.; Bonkovsky, H.L. Effects of silymarin on hepatitis c virus and haem oxygenase-1 gene expression in human hepatoma cells. Liv. Int. Off. J. Int. Assoc. Study Liv. 2009, 29, 366–373. [CrossRef] [PubMed]
31. Wagoner, J.; Negash, A.; Kane, O.J.; Martinez, L.E.; Nahmias, Y.; Bourne, N.; Owen, D.M.; Grove, J.; Brimacombe, C.; McKeating, J.A., et al. Multiple effects of silymarin on the hepatitis c virus lifecycle. Hepatology 2010, 51, 1912–1921. [CrossRef] [PubMed]
32. Mayer, K.E.; Myers, R.P.; Lee, S.S. Silymarin treatment of viral hepatitis: A systematic review. J. Viral Hepat. 2005, 12, 559–567. [CrossRef] [PubMed]
33. Strickland, G.T.; Tanamly, M.D.; Tadros, F.; Labeeb, S.; Makld, H.; Nessim, D.; Mikhail, N.; Magder, L.S.; Afdhal, N.H.; Medhat, A., et al. Two-year results of a randomised double-blinded trial evaluating silymarin for chronic hepatitis c. Dig. Liv. Dis. Off. J. Ital. Soc. Gastroenterol. Ital. Assoc. Study Liv. 2005, 37, 542–543. [CrossRef] [PubMed]
34. Adeyemo, O.; Doi, H.; Rajender Reddy, K.; Kaplan, D.E. Impact of oral silymarin on virus- and non-virus-specific t-cell responses in chronic hepatitis c infection. J. Viral Hepat. 2013, 20, 453–462. [CrossRef] [PubMed]
35. Wei, F.; Liu, S.K.; Liu, X.Y.; Li, Z.J.; Li, B.; Zhou, Y.L.; Zhang, H.Y.; Li, Y.W. Meta-analysis: Silymarin and its combination therapy for the treatment of chronic hepatitis b. Eur. J. Clin. Microbiol. Infect. Dis. Off. Publ. Eur. Soc. Clin. Microbiol. 2013, 32, 657–669. [CrossRef] [PubMed]
36. Blaising, J.; Levy, P.L.; Gondeau, C.; Phelip, C.; Varbanov, M.; Teissier, E.; Ruggiero, F.; Polyak, S.J.; Oberlies, N.H.; Ivanovic, T., et al. Silibinin inhibits hepatitis c virus entry into hepatocytes by hindering clathrin-dependent trafficking. Cell. Microbiol. 2013, 15, 1866–1882. [CrossRef] [PubMed]
37. Buzzelli, G.; Moscarella, S.; Giusti, A.; Duchini, A.; Marena, C.; Lampertico, M. A pilot study on the liver protective effect of silybin-phosphatidylcholine complex (idb1016) in chronic active hepatitis. Int. J. Clin. Pharmacol. Ther. Toxicol. 1993, 31, 456–460. [PubMed]
38. Liu, S.; Wei, W.; Li, Y.; Lin, X.; Shi, K.; Cao, X.; Zhou, M. In vitro and in vivo anti-hepatitis b virus activities of the lignan nirtetralin b isolated from phyllanthus niruri l. J. Ethnopharmacol. 2014, 157, 62–68. [CrossRef] [PubMed]
39. Ibrahim, D.; Hong, L.S.; Kuppan, N. Antimicrobial activity of crude methanolic extract from phyllanthus niruri. Nat. Prod. Commun. 2013, 8, 493–496. [PubMed]
40. Manjrekar, A.P.; Jisha, V.; Bag, P.P.; Adhikary, B.; Pai, M.M.; Hegde, A.; Nandini, M. Effect of phyllanthus niruri linn. Treatment on liver, kidney and testes in ccl4 induced hepatotoxic rats. Indian J. Exp. Biol. 2008, 46, 514–520. [PubMed]
41. Amin, Z.A.; Abdulla, M.A.; Ali, H.M.; Alshawsh, M.A.; Qadir, S.W. Assessment of in vitro antioxidant, antibacterial and immune activation potentials of aqueous and ethanol extracts of phyllanthus niruri. J. Sci. Food Agric. 2012, 92, 1874–1877. [CrossRef] [PubMed]
42. Lam, W.Y.; Leung, K.T.; Law, P.T.; Lee, S.M.; Chan, H.L.; Fung, K.P.; Ooi, V.E.; Waye, M.M. Antiviral effect of phyllanthus nanus ethanolic extract against hepatitis b virus (hbv) by expression microarray analysis. J. Cell. Biochem. 2006, 97, 795–812. [CrossRef] [PubMed]
43. Liu, J.; Lin, H.; McIntosh, H. Genus phyllanthus for chronic hepatitis b virus infection: A systematic review. J. Viral Hepat. 2001, 8, 358–366. [CrossRef] [PubMed]
44. Zhang, H.; Li, C.; Kwok, S.T.; Zhang, Q.W.; Chan, S.W. A review of the pharmacological effects of the dried root of polygonum cuspidatum (hu zhang) and its constituents. Evid. Based Complement. Altern. Med. eCAM 2013, 2013, 208349. [CrossRef] [PubMed]
45. Peng, W.; Qin, R.; Li, X.; Zhou, H. Botany, phytochemistry, pharmacology, and potential application of polygonum cuspidatum sieb.Et zucc.: A review. J. Ethnopharmacol. 2013, 148, 729–745. [CrossRef] [PubMed]
46. Zhang, L.; Wang, G.; Hou, W.; Li, P.; Dulin, A.; Bonkovsky, H.L. Contemporary clinical research of traditional chinese medicines for chronic hepatitis b in china: An analytical review. Hepatology 2010, 51, 690–698. [CrossRef] [PubMed]
47. Chang, J.S.; Liu, H.W.; Wang, K.C.; Chen, M.C.; Chiang, L.C.; Hua, Y.C.; Lin, C.C. Ethanol extract of polygonum cuspidatum inhibits hepatitis b virus in a stable hbv-producing cell line. Antivir. Res. 2005, 66, 29–34. [CrossRef] [PubMed]
48. Lin, L.; Cai, W.M.; Qin, C.J.; Miao, L.C.; Yun, L.T.; Hua, Y.; Weilin, L. Intervention of tlr4 signal pathway cytokines in severe liver injury with obstructive jaundice in rats. Int. J. Sports Med. 2012, 33, 572–579. [CrossRef] [PubMed]
49. Liu, C.T.; Chuang, P.T.; Wu, C.Y.; Weng, Y.M.; Chen, W.; Tseng, C.Y. Antioxidative and in vitro hepatoprotective activity of bupleurum kaoi leaf infusion. Phytother. Res. PTR 2006, 20, 1003–1008. [CrossRef] [PubMed]
50. Chiang, L.C.; Ng, L.T.; Liu, L.T.; Shieh, D.E.; Lin, C.C. Cytotoxicity and anti-hepatitis b virus activities of saikosaponins from bupleurum species. Planta Med. 2003, 69, 705–709. [PubMed]
51. Lin, L.T.; Chung, C.Y.; Hsu, W.C.; Chang, S.P.; Hung, T.C.; Shields, J.; Russell, R.S.; Lin, C.C.; Li, C.F.; Yen, M.H., et al. Saikosaponin b2 is a naturally occurring terpenoid that efficiently inhibits hepatitis c virus entry. J. Hepatol. 2015, 62, 541–548. [CrossRef] [PubMed]
52. Yue, S.; Hu, B.; Wang, Z.; Yue, Z.; Wang, F.; Zhao, Y.; Yang, Z.; Shen, M. Salvia miltiorrhiza compounds protect the liver from acute injury by regulation of p38 and nfkappab signaling in kupffer cells. Pharm. Biol. 2014, 52, 1278–1285. [CrossRef] [PubMed]
53. Zhang, Y.; Zhang, Y.; Xie, Y.; Gao, Y.; Ma, J.; Yuan, J.; Li, J.; Wang, J.; Li, L.; Zhang, J., et al. Multitargeted inhibition of hepatic fibrosis in chronic iron-overloaded mice by salvia miltiorrhiza. J. Ethnopharmacol. 2013, 148, 671–681. [CrossRef] [PubMed]
54. Ma, Z.J.; Li, Q.; Wang, J.B.; Zhao, Y.L.; Zhong, Y.W.; Bai, Y.F.; Wang, R.L.; Li, J.Y.; Yang, H.Y.; Zeng, L.N., et al. Combining oxymatrine or matrine with lamivudine increased its antireplication effect against the hepatitis b virus in vitro. Evid. Based Complement. Altern. Med. eCAM 2013, 2013, 186573.
55. Suo, Z.; Liu, Y.; Ferreri, M.; Zhang, T.; Liu, Z.; Mu, X.; Han, B. Impact of matrine on inflammation related factors in rat intestinal microvascular endothelial cells. J. Ethnopharmacol. 2009, 125, 404–409. [CrossRef] [PubMed]
56. Yao, N.; Wang, X. In vitro immunomodulatory activity of oxymatrine on toll-like receptor 9 signal pathway in chronic hepatitis b. Am. J. Chin. Med. 2014, 42, 1399–1410. [CrossRef] [PubMed]
57. Wan, J.; Zhu, Y.N.; Feng, J.Q.; Chen, H.J.; Zhang, R.J.; Ni, J.; Chen, Z.H.; Hou, L.F.; Liu, Q.F.; Zhang, J., et al. Periplocoside a, a pregnane glycoside from periploca sepium bge, prevents concanavalin a-induced mice hepatitis through inhibiting nkt-derived inflammatory cytokine productions. Int. Immunopharmacol. 2008, 8, 1248–1256. [CrossRef] [PubMed]
58. Zhang, J.; Ni, J.; Chen, Z.H.; Li, X.; Zhang, R.J.; Tang, W.; Zhao, W.M.; Yang, Y.F.; Zuo, J.P. Periplocoside a prevents experimental autoimmune encephalomyelitis by suppressing il-17 production and inhibits differentiation of th17 cells. Acta Pharmacol. Sin. 2009, 30, 1144–1152. [CrossRef] [PubMed]
59. Ai, Z.L.; Zhang, W.S.; Yao, S.K.; Xie, B.S.; Gao, C. [effect of baicalin on liver fatty acid binding protein in oxidative stress model in vitro]. Chin. J. Hepatol. 2011, 19, 927–931.
60. Kim, S.J.; Moon, Y.J.; Lee, S.M. Protective effects of baicalin against ischemia/reperfusion injury in rat liver. J. Nat. Prod. 2010, 73, 2003–2008. [CrossRef] [PubMed]
61. Zhao, Y.; Li, H.; Gao, Z.; Xu, H. Effects of dietary baicalin supplementation on iron overload-induced mouse liver oxidative injury. Eur. J. Pharmacol. 2005, 509, 195–200. [CrossRef] [PubMed]
62. Huang, H.L.; Wang, Y.J.; Zhang, Q.Y.; Liu, B.; Wang, F.Y.; Li, J.J.; Zhu, R.Z. Hepatoprotective effects of baicalein against ccl(4)-induced acute liver injury in mice. World J. Gastroenterol. WJG 2012, 18, 6605–6613. [CrossRef] [PubMed]
63. Wu, Y.L.; Lian, L.H.; Wan, Y.; Nan, J.X. Baicalein inhibits nuclear factor-kappab and apoptosis via c-flip and mapk in d-galn/lps induced acute liver failure in murine models. Chem. Biol. Interact. 2010, 188, 526–534. [CrossRef] [PubMed]
64. Yim, S.Y.; Lee, Y.J.; Lee, Y.K.; Jung, S.E.; Kim, J.H.; Kim, H.J.; Son, B.G.; Park, Y.H.; Lee, Y.G.; Choi, Y.W., et al. Gomisin n isolated from schisandra chinensis significantly induces anti-proliferative and pro-apoptotic effects in hepatic carcinoma. Mol. Med. Rep. 2009, 2, 725–732. [PubMed]
65. Xue, Y.; Li, X.; Du, X.; Li, X.; Wang, W.; Yang, J.; Chen, J.; Pu, J.; Sun, H. Isolation and anti-hepatitis b virus activity of dibenzocyclooctadiene lignans from the fruits of schisandra chinensis. Phytochemistry 2015, 116, 253–261. [CrossRef] [PubMed]
66. Checker, R.; Patwardhan, R.S.; Sharma, D.; Menon, J.; Thoh, M.; Bhilwade, H.N.; Konishi, T.; Sandur, S.K. Schisandrin b exhibits anti-inflammatory activity through modulation of the redox-sensitive transcription factors nrf2 and nf-kappab. Free Radic. Biol. Med. 2012, 53, 1421–1430. [CrossRef] [PubMed]
67. Cai, L.; Cao, B.; Lin, D. Effects of traditional chinese medicine huangqi injection (radix astragali) on random skin flap survival in rats. J. Reconstr. Microsurg. 2015, 31, 565–570. [CrossRef] [PubMed]
68. Yu, K.Z.; Liu, J.; Guo, B.L.; Zhao, Z.Z.; Hong, H.; Chen, H.B.; Cai, S.Q. Microscopic research on a multi-source traditional chinese medicine, astragali radix. J. Nat. Med. 2014, 68, 340–350. [CrossRef] [PubMed]
69. Gao, J.; Liu, Z.J.; Chen, T.; Zhao, D. Pharmaceutical properties of calycosin, the major bioactive isoflavonoid in the dry root extract of radix astragali. Pharm. Biol. 2014, 52, 1217–1222. [CrossRef] [PubMed]
70. Liu, Z.Y. [progress in pharmacological research on radix astragali]. Chin. J. Mod. Dev. Tradit. Med. 1991, 11, 312–314.
71. Tang, L.L.; Sheng, J.F.; Xu, C.H.; Liu, K.Z. Clinical and experimental effectiveness of astragali compound in the treatment of chronic viral hepatitis b. J. Int. Med. Res. 2009, 37, 662–667. [CrossRef] [PubMed]
72. Wang, S.; Li, J.; Huang, H.; Gao, W.; Zhuang, C.; Li, B.; Zhou, P.; Kong, D. Anti-hepatitis b virus activities of astragaloside iv isolated from radix astragali. Biol. Pharm. Bull. 2009, 32, 132–135. [CrossRef] [PubMed]
73. Bobe, G.; Young, J.W.; Beitz, D.C. Invited review: Pathology, etiology, prevention, and treatment of fatty liver in dairy cows. J. Dairy Sci. 2004, 87, 3105–3124. [CrossRef]
74. Bellentani, S.; Bedogni, G.; Miglioli, L.; Tiribelli, C. The epidemiology of fatty liver. Eur. J. Gastroenterol. Hepatol. 2004, 16, 1087–1093. [CrossRef] [PubMed]
75. Bedogni, G.; Miglioli, L.; Masutti, F.; Tiribelli, C.; Marchesini, G.; Bellentani, S. Prevalence of and risk factors for nonalcoholic fatty liver disease: The dionysos nutrition and liver study. Hepatology 2005, 42, 44–52. [CrossRef] [PubMed]
76. Levene, A.P.; Goldin, R.D. The epidemiology, pathogenesis and histopathology of fatty liver disease. Histopathology 2012, 61, 141–152. [CrossRef] [PubMed]
77. Yeh, M.M.; Brunt, E.M. Pathological features of fatty liver disease. Gastroenterology 2014, 147, 754–764. [CrossRef] [PubMed]
78. Park, K.S.; Lee, Y.S.; Park, H.W.; Seo, S.H.; Jang, B.G.; Hwang, J.Y.; Cho, K.B.; Hwang, J.S.; Ahn, S.H.; Kang, Y.N., et al. Factors associated or related to with pathological severity of nonalcoholic fatty liver disease. Korean J. Intern. Med. 2004, 19, 19–26. [CrossRef] [PubMed]
79. Corrado, R.L.; Torres, D.M.; Harrison, S.A. Review of treatment options for nonalcoholic fatty liver disease. Med. Clin. N. Am. 2014, 98, 55–72. [CrossRef] [PubMed]
80. Younossi, Z.M. Review article: Current management of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. Aliment. Pharmacol. Ther. 2008, 28, 2–12. [CrossRef] [PubMed]
81. Fan, H.; Chen, Y.Y.; Bei, W.J.; Wang, L.Y.; Chen, B.T.; Guo, J. In vitro screening for antihepatic steatosis active components within coptidis rhizoma alkaloids extract using liver cell extraction with hplc analysis and a free fatty acid-induced hepatic steatosis hepg2 cell assay. Evid. Based Complement. Altern. Med. eCAM 2013, 2013, 459390.
82. Xing, L.J.; Zhang, L.; Liu, T.; Hua, Y.Q.; Zheng, P.Y.; Ji, G. Berberine reducing insulin resistance by up-regulating irs-2 mrna expression in nonalcoholic fatty liver disease (nafld) rat liver. Eur. J. Pharmacol. 2011, 668, 467–471. [CrossRef] [PubMed]
83. Xue, M.; Zhang, L.; Yang, M.X.; Zhang, W.; Li, X.M.; Ou, Z.M.; Li, Z.P.; Liu, S.H.; Li, X.J.; Yang, S.Y. Berberine-loaded solid lipid nanoparticles are concentrated in the liver and ameliorate hepatosteatosis in db/db mice. Int. J. Nanomed. 2015, 10, 5049–5057. [CrossRef] [PubMed]
84. Wang, M.; Wang, F.; Wang, Y.; Ma, X.; Zhao, M.; Zhao, C. Metabonomics study of the therapeutic mechanism of gynostemma pentaphyllum and atorvastatin for hyperlipidemia in rats. PLoS ONE 2013, 8, e78731. [CrossRef] [PubMed]
85. Muller, C.; Gardemann, A.; Keilhoff, G.; Peter, D.; Wiswedel, I.; Schild, L. Prevention of free fatty acid-induced lipid accumulation, oxidative stress, and cell death in primary hepatocyte cultures by a gynostemma pentaphyllum extract. Phytomed. Int. J. Phytother. Phytopharmacol. 2012, 19, 395–401. [CrossRef] [PubMed]
86. Chou, S.C.; Chen, K.W.; Hwang, J.S.; Lu, W.T.; Chu, Y.Y.; Lin, J.D.; Chang, H.J.; See, L.C. The add-on effects of gynostemma pentaphyllum on nonalcoholic fatty liver disease. Altern. Ther. Health Med. 2006, 12, 34–39. [PubMed]
87. Malek, M.A.; Hoang, M.H.; Jia, Y.; Lee, J.H.; Jun, H.J.; Lee, D.H.; Lee, H.J.; Lee, C.; Lee, M.K.; Hwang, B.Y., et al. Ombuin-3-o-beta-d-glucopyranoside from gynostemma pentaphyllum is a dual agonistic ligand of peroxisome proliferator-activated receptors α and δ/β. Biochem. Biophys. Res. Commun. 2013, 430, 1322–1328. [CrossRef] [PubMed]
88. Ding, R.B.; Tian, K.; Cao, Y.W.; Bao, J.L.; Wang, M.; He, C.; Hu, Y.; Su, H.; Wan, J.B. Protective effect of panax notoginseng saponins on acute ethanol-induced liver injury is associated with ameliorating hepatic lipid accumulation and reducing ethanol-mediated oxidative stress. J. Agric. Food Chem. 2015, 63, 2413–2422. [CrossRef] [PubMed]
89. Yang, X.; Liao, M.; Yang, Z.; Guo, J.; Gao, Q. [effect of panax notoginseng on genes expression of cyp and gst in liver tissues of rats]. China J. Chin. Mater. Med. 2009, 34, 2390–2393.
90. Shi, K.Q.; Fan, Y.C.; Liu, W.Y.; Li, L.F.; Chen, Y.P.; Zheng, M.H. Traditional chinese medicines benefit to nonalcoholic fatty liver disease: A systematic review and meta-analysis. Mol. Biol. Rep. 2012, 39, 9715–9722. [CrossRef] [PubMed]
91. Li, T.; Li, S.; Dong, Y.; Zhu, R.; Liu, Y. Antioxidant activity of penta-oligogalacturonide, isolated from haw pectin, suppresses triglyceride synthesis in mice fed with a high-fat diet. Food Chem. 2014, 145, 335–341. [CrossRef] [PubMed]
92. Li, T.P.; Zhu, R.G.; Dong, Y.P.; Liu, Y.H.; Li, S.H.; Chen, G. Effects of pectin pentaoligosaccharide from hawthorn (crataegus pinnatifida bunge. Var. Major) on the activity and mrna levels of enzymes involved in fatty acid oxidation in the liver of mice fed a high-fat diet. J. Agric. Food Chem. 2013, 61, 7599–7605. [PubMed]
93. Liu, M.; Xu, L.; Yin, L.; Qi, Y.; Xu, Y.; Han, X.; Zhao, Y.; Sun, H.; Yao, J.; Lin, Y., et al. Potent effects of dioscin against obesity in mice. Sci. Rep. 2015, 5, 7973. [PubMed]
94. Xu, T.; Zheng, L.; Xu, L.; Yin, L.; Qi, Y.; Xu, Y.; Han, X.; Peng, J. Protective effects of dioscin against alcohol-induced liver injury. Arch. Toxicol. 2014, 88, 739–753. [PubMed]
95. Chao, J.; Huo, T.I.; Cheng, H.Y.; Tsai, J.C.; Liao, J.W.; Lee, M.S.; Qin, X.M.; Hsieh, M.T.; Pao, L.H.; Peng, W.H. Gallic acid ameliorated impaired glucose and lipid homeostasis in high fat diet-induced nafld mice. PLoS ONE 2014, 9, e96969. [CrossRef] [PubMed]
96. Hsu, C.L.; Yen, G.C. Effect of gallic acid on high fat diet-induced dyslipidaemia, hepatosteatosis and oxidative stress in rats. Br. J. Nutr. 2007, 98, 727–735. [CrossRef] [PubMed]
97. Ye, H.J.; Wei, S.L.; Wang, H.C.; Liu, X.Y.; Wan, H.J.; Yi, X.R.; Yuan, Y.C.; Kong, X.P. [therapeutic effects of compound glycyrrhizin liposome on fibrosis of the rats with nonalcoholic steatohepatitis]. Chin. J. Hepatol. 2009, 17, 877–878.
98. Korenaga, M.; Hidaka, I.; Nishina, S.; Sakai, A.; Shinozaki, A.; Gondo, T.; Furutani, T.; Kawano, H.; Sakaida, I.; Hino, K. A glycyrrhizin-containing preparation reduces hepatic steatosis induced by hepatitis c virus protein and iron in mice. Liv. Int. Off. J. Int. Assoc. Study Liv. 2011, 31, 552–560. [CrossRef] [PubMed]
99. Feher, J.; Lengyel, G. Silymarin in the treatment of chronic liver diseases: Past and future. Orv. Hetil. 2008, 149, 2413–2418. [CrossRef] [PubMed]
100. Serviddio, G.; Bellanti, F.; Giudetti, A.M.; Gnoni, G.V.; Petrella, A.; Tamborra, R.; Romano, A.D.; Rollo, T.; Vendemiale, G.; Altomare, E. A silybin-phospholipid complex prevents mitochondrial dysfunction in a rodent model of nonalcoholic steatohepatitis. J. Pharmacol. Exp.Ther. 2010, 332, 922–932. [CrossRef] [PubMed]
101. Loguercio, C.; Federico, A.; Trappoliere, M.; Tuccillo, C.; de Sio, I.; di Leva, A.; Niosi, M.; D’Auria, M.V.; Capasso, R.; Del Vecchio Blanco, C., et al. The effect of a silybin-vitamin e-phospholipid complex on nonalcoholic fatty liver disease: A pilot study. Dig. Dis. Sci. 2007, 52, 2387–2395. [CrossRef] [PubMed]
102. Shtroblia, A.L.; Fira, L.S.; Likhatskii, P.G.; Pyla, V.P.; Vashkeba, E.M.; Medvid, II. Studying of hepatoprotective properties of dry extract from apricot leaves on the model of liver lesion by tetrachloromethane. V. Ross. Akad. Med. Nauk Ross. 2013, 3, 68–72.
103. Ozturk, F.; Gul, M.; Ates, B.; Ozturk, I.C.; Cetin, A.; Vardi, N.; Otlu, A.; Yilmaz, I. Protective effect of apricot (prunus armeniaca l.) on hepatic steatosis and damage induced by carbon tetrachloride in wistar rats. Br. J. Nutr. 2009, 102, 1767–1775. [CrossRef] [PubMed]
104. Hokari, A.; Ishikawa, T.; Tajiri, H.; Matsuda, T.; Ishii, O.; Matsumoto, N.; Okuse, C.; Takahashi, H.; Kurihara, T.; Kawahara, K., et al. Efficacy of mk615 for the treatment of patients with liver disorders. World J. Gastroenterol. WJG 2012, 18, 4118–4126. [CrossRef] [PubMed]
105. Liu, D.H.; Luo, Y.H.; Liang, J.C.; Huang, Y.K. Baicalin regulates lipid metabolism in high-fat feeding sd rat liver and the mechanism involves modulation of ampk-alpha pathway. Chin. J. Hepatol. 2010, 18, 711–712.
106. Guo, H.X.; Liu, D.H.; Ma, Y.; Liu, J.F.; Wang, Y.; Du, Z.Y.; Wang, X.; Shen, J.K.; Peng, H.L. Long-term baicalin administration ameliorates metabolic disorders and hepatic steatosis in rats given a high-fat diet. Acta Pharmacol. Sin. 2009, 30, 1505–1512. [PubMed]
107. Xi, Y.; Wu, M.; Li, H.; Dong, S.; Luo, E.; Gu, M.; Shen, X.; Jiang, Y.; Liu, Y.; Liu, H. Baicalin attenuates high fat diet-induced obesity and liver dysfunction: Dose-response and potential role of camkkbeta/ampk/acc pathway. Cell. Physiol. Biochem. Int. J. Exp. Cell. Physiol. Biochem. Pharmacol. 2015, 35, 2349–2359. [CrossRef] [PubMed]
108. Kim, S.J.; Lee, S.M. Effect of baicalin on toll-like receptor 4-mediated ischemia/reperfusion inflammatory responses in alcoholic fatty liver condition. Toxicol. Appl. Pharmacol. 2012, 258, 43–50. [CrossRef] [PubMed]
109. Sivanathan, V.; Kittner, J.M.; Sprinzl, M.F.; Weinmann, A.; Koch, S.; Wiltink, J.; Nguyen-Tat, M.; Marquardt, J.U.; Worns, M.A.; Zimmermann, T., et al. Etiology and complications of liver cirrhosis: Data from a german centre. Dtsch. Med. Wochenschr. 2014, 139, 1758–1762. [PubMed]
110. Wang, X.; Lin, S.X.; Tao, J.; Wei, X.Q.; Liu, Y.T.; Chen, Y.M.; Wu, B. Study of liver cirrhosis over ten consecutive years in southern china. World J. Gastroenterol. WJG 2014, 20, 13546–13555. [CrossRef] [PubMed]
111. Mokdad, A.A.; Lopez, A.D.; Shahraz, S.; Lozano, R.; Mokdad, A.H.; Stanaway, J.; Murray, C.J.; Naghavi, M. Liver cirrhosis mortality in 187 countries between 1980 and 2010: A systematic analysis. BMC Med. 2014, 12, 145. [CrossRef] [PubMed]
112. Pruszczynski, A. Histogenesis and pathological anatomy of liver cirrhosis. Pol. Arch. Med. Wewn. 1962, 32, 1379–1388. [PubMed]
113. Bataller, R.; Schwabe, R.F.; Choi, Y.H.; Yang, L.; Paik, Y.H.; Lindquist, J.; Qian, T.; Schoonhoven, R.; Hagedorn, C.H.; Lemasters, J.J., et al. Nadph oxidase signal transduces angiotensin ii in hepatic stellate cells and is critical in hepatic fibrosis. J. Clin. Investig. 2003, 112, 1383–1394. [CrossRef] [PubMed]
114. Marra, F.; Arrighi, M.C.; Fazi, M.; Caligiuri, A.; Pinzani, M.; Romanelli, R.G.; Efsen, E.; Laffi, G.; Gentilini, P. Extracellular signal-regulated kinase activation differentially regulates platelet-derived growth factor’s actions in hepatic stellate cells, and is induced by in vivo liver injury in the rat. Hepatology 1999, 30, 951–958. [CrossRef] [PubMed]
115. Schnabl, B.; Kweon, Y.O.; Frederick, J.P.; Wang, X.F.; Rippe, R.A.; Brenner, D.A. The role of smad3 in mediating mouse hepatic stellate cell activation. Hepatology 2001, 34, 89–100. [CrossRef] [PubMed]
116. Marra, F.; Efsen, E.; Romanelli, R.G.; Caligiuri, A.; Pastacaldi, S.; Batignani, G.; Bonacchi, A.; Caporale, R.; Laffi, G.; Pinzani, M., et al. Ligands of peroxisome proliferator-activated receptor gamma modulate profibrogenic and proinflammatory actions in hepatic stellate cells. Gastroenterology 2000, 119, 466–478. [CrossRef] [PubMed]
117. Paik, Y.H.; Schwabe, R.F.; Bataller, R.; Russo, M.P.; Jobin, C.; Brenner, D.A. Toll-like receptor 4 mediates inflammatory signaling by bacterial lipopolysaccharide in human hepatic stellate cells. Hepatology 2003, 37, 1043–1055. [CrossRef] [PubMed]
118. Boya, P.; Larrea, E.; Sola, I.; Majano, P.L.; Jimenez, C.; Civeira, M.P.; Prieto, J. Nuclear factor- κb in the liver of patients with chronic hepatitis c: Decreased rela expression is associated with enhanced fibrosis progression. Hepatology 2001, 34, 1041–1048. [CrossRef] [PubMed]
119. Fialla, A.D.; Israelsen, M.; Hamberg, O.; Krag, A.; Gluud, L.L. Nutritional therapy in cirrhosis or alcoholic hepatitis: A systematic review and meta-analysis. Liv. Int. Off. J. Int. Assoc. Study Liv. 2015, 35, 2072–2078. [CrossRef] [PubMed]
120. Feng, Y.; Wang, N.; Ye, X.; Li, H.; Feng, Y.; Cheung, F.; Nagamatsu, T. Hepatoprotective effect and its possible mechanism of coptidis rhizoma aqueous extract on carbon tetrachloride-induced chronic liver hepatotoxicity in rats. J. Ethnopharmacol. 2011, 138, 683–690. [CrossRef] [PubMed]
121. Ye, X.; Feng, Y.; Tong, Y.; Ng, K.M.; Tsao, S.; Lau, G.K.; Sze, C.; Zhang, Y.; Tang, J.; Shen, J.; et al. Hepatoprotective effects of coptidis rhizoma aqueous extract on carbon tetrachloride-induced acute liver hepatotoxicity in rats. J. Ethnopharmacol. 2009, 124, 130–136. [CrossRef] [PubMed]
122. Zhang, B.J.; Xu, D.; Guo, Y.; Ping, J.; Chen, L.B.; Wang, H. Protection by and anti-oxidant mechanism of berberine against rat liver fibrosis induced by multiple hepatotoxic factors. Clin. Exp. Pharmacol. Physiol. 2008, 35, 303–309. [CrossRef] [PubMed]
123. Li, J.; Pan, Y.; Kan, M.; Xiao, X.; Wang, Y.; Guan, F.; Zhang, X.; Chen, L. Hepatoprotective effects of berberine on liver fibrosis via activation of amp-activated protein kinase. Life Sci. 2014, 98, 24–30. [CrossRef] [PubMed]
124. Wang, N.; Feng, Y.; Cheung, F.; Chow, O.Y.; Wang, X.; Su, W.; Tong, Y. A comparative study on the hepatoprotective action of bear bile and coptidis rhizoma aqueous extract on experimental liver fibrosis in rats. BMC Complement. Altern. Med. 2012, 12, 239. [CrossRef] [PubMed]
125. Guo, C.; Xu, L.; He, Q.; Liang, T.; Duan, X.; Li, R. Anti-fibrotic effects of puerarin on ccl4-induced hepatic fibrosis in rats possibly through the regulation of ppar-gamma expression and inhibition of pi3k/akt pathway. Food Chem. Toxicol. An Int. J. Publ. Br. Ind. Biol. Res. Assoc. 2013, 56, 436–442. [CrossRef] [PubMed]
126. Li, R.; Xu, L.; Liang, T.; Li, Y.; Zhang, S.; Duan, X. Puerarin mediates hepatoprotection against ccl4-induced hepatic fibrosis rats through attenuation of inflammation response and amelioration of metabolic function. Food Chem. Toxicol. An Int. J. Publ. Br. Ind. Biol. Res. Assoc. 2013, 52, 69–75. [CrossRef] [PubMed]
127. Zhang, S.; Ji, G.; Liu, J. Reversal of chemical-induced liver fibrosis in wistar rats by puerarin. J. Nutr. Biochem. 2006, 17, 485–491. [CrossRef] [PubMed]
128. Kwon, R.H.; Ha, B.J. Protection of saururus chinensis extract against liver oxidative stress in rats of triton wr-1339-induced hyperlipidemia. Toxicol. Res. 2014, 30, 291–296. [CrossRef] [PubMed]
129. Lu, Y.; Hong, T.G.; Jin, M.; Yang, J.H.; Suh, S.J.; Piao, D.G.; Ko, H.K.; Seo, C.S.; Chang, Y.C.; Kim, C.H., et al. Saucerneol g, a new lignan, from saururus chinensis inhibits matrix metalloproteinase-9 induction via a nuclear factor kappab and mitogen activated protein kinases in lipopolysaccharide-stimulated raw264.7 cells. Biol. Pharm. Bull. 2010, 33, 1944–1948. [CrossRef] [PubMed]
130. Wang, L.; Cheng, D.; Wang, H.; di, L.; Zhou, X.; Xu, T.; Yang, X.; Liu, Y. The hepatoprotective and antifibrotic effects of saururus chinensis against carbon tetrachloride induced hepatic fibrosis in rats. J. Ethnopharmacol. 2009, 126, 487–491. [CrossRef] [PubMed]
131. Wang, J.; Guo, J.; Liu, S. [inhibitory effect of glycyrrhizin on nf-kappa b binding activity in ccl4 plus ethanol induced liver cirrhosis in rats]. Chin. J. Hepatol. 1999, 7, 42–43.
132. Qu, Y.; Zong, L.; Xu, M.; Dong, Y.; Lu, L. Effects of 18alpha-glycyrrhizin on tgf-beta1/smad signaling pathway in rats with carbon tetrachloride-induced liver fibrosis. Int. J. Clin. Exp. Pathol. 2015, 8, 1292–1301. [PubMed]
133. Manns, M.P.; Wedemeyer, H.; Singer, A.; Khomutjanskaja, N.; Dienes, H.P.; Roskams, T.; Goldin, R.; Hehnke, U.; Inoue, H.; European, S.S.G. Glycyrrhizin in patients who failed previous interferon alpha-based therapies: Biochemical and histological effects after 52 weeks. J. Viral Hepat. 2012, 19, 537–546. [CrossRef] [PubMed]
134. Serviddio, G.; Bellanti, F.; Stanca, E.; Lunetti, P.; Blonda, M.; Tamborra, R.; Siculella, L.; Vendemiale, G.; Capobianco, L.; Giudetti, A.M. Silybin exerts antioxidant effects and induces mitochondrial biogenesis in liver of rat with secondary biliary cirrhosis. Free Radic.Biol. Med. 2014, 73, 117–126. [CrossRef] [PubMed]
135. Stanca, E.; Serviddio, G.; Bellanti, F.; Vendemiale, G.; Siculella, L.; Giudetti, A.M. Down-regulation of lpcat expression increases platelet-activating factor level in cirrhotic rat liver: Potential antiinflammatory effect of silybin. Biochim. Biophys. Acta 2013, 1832, 2019–2026. [CrossRef] [PubMed]
136. Seeff, L.B.; Curto, T.M.; Szabo, G.; Everson, G.T.; Bonkovsky, H.L.; Dienstag, J.L.; Shiffman, M.L.; Lindsay, K.L.; Lok, A.S.; Di Bisceglie, A.M., et al. Herbal product use by persons enrolled in the hepatitis c antiviral long-term treatment against cirrhosis (halt-c) trial. Hepatology 2008, 47, 605–612. [CrossRef] [PubMed]
137. Pares, A.; Planas, R.; Torres, M.; Caballeria, J.; Viver, J.M.; Acero, D.; Panes, J.; Rigau, J.; Santos, J.; Rodes, J. Effects of silymarin in alcoholic patients with cirrhosis of the liver: Results of a controlled, double-blind, randomized and multicenter trial. J. Hepatol. 1998, 28, 615–621. [CrossRef]
138. Yen, M.H.; Weng, T.C.; Liu, S.Y.; Chai, C.Y.; Lin, C.C. The hepatoprotective effect of bupleurum kaoi, an endemic plant to taiwan, against dimethylnitrosamine-induced hepatic fibrosis in rats. Biol. Pharm. Bull. 2005, 28, 442–448. [CrossRef] [PubMed]
139. Wang, X.; Wang, Q.; Burczynski, F.J.; Kong, W.; Gong, Y. Saikosaponin a of bupleurum chinense (chaihu) elevates bone morphogenetic protein 4 (bmp-4) during hepatic stellate cell activation. Phytomed. Int. J. Phytother. Phytopharm. 2013, 20, 1330–1335. [CrossRef] [PubMed]
140. Zhao, M.Q.; Han, D.W.; Ma, X.H.; Zhao, Y.C.; Yin, L.; Li, C.M. Preventive and therapeutic actions of glycyrrhizin, glycyrrhetic acid and crude saikosides on experimental liver cirrhosis in rats. Acta Pharm. Sin. 1983, 18, 325–331.
141. Wu, S.J.; Lin, Y.H.; Chu, C.C.; Tsai, Y.H.; Chao, J.C. Curcumin or saikosaponin a improves hepatic antioxidant capacity and protects against ccl4-induced liver injury in rats. J. Med. Food 2008, 11, 224–229. [CrossRef] [PubMed]
142. Parajuli, D.R.; Zhao, Y.Z.; Jin, H.; Chi, J.H.; Li, S.Y.; Kim, Y.C.; Sohn, D.H.; Lee, S.H. Anti-fibrotic effect of pf2401-sf, a standardized fraction of salvia miltiorrhiza, in thioacetamide-induced experimental rats liver fibrosis. Arch. Pharm. Res. 2015, 38, 549–555. [CrossRef] [PubMed]
143. Xiping, Z.; Jie, Z.; Shuyun, Y.; Qili, W.; Guanghua, F.; Yan, P. Influence of salvia miltiorrhizae on the mesenteric lymph node of rats with severe acute pancreatitis or obstructive jaundice. Med. Inflamm. 2009, 2009, 675195.
144. Nan, J.X.; Park, E.J.; Kim, Y.C.; Ko, G.; Sohn, D.H. Scutellaria baicalensis inhibits liver fibrosis induced by bile duct ligation or carbon tetrachloride in rats. J. Pharm. Pharmacol. 2002, 54, 555–563. [CrossRef] [PubMed]
145. Pan, T.L.; Wang, P.W.; Leu, Y.L.; Wu, T.H.; Wu, T.S. Inhibitory effects of scutellaria baicalensis extract on hepatic stellate cells through inducing g2/m cell cycle arrest and activating erk-dependent apoptosis via bax and caspase pathway. J. Ethnopharmacol. 2012, 139, 829–837. [CrossRef] [PubMed]
146. Zhang, Y.F.; Zhou, S.Z.; Cheng, X.Y.; Yi, B.; Shan, S.Z.; Wang, J.; Li, Q.F. Baicalein attenuates hypertrophic scar formation via inhibiting tgf-beta/smad2/3 signaling pathway. Br. J. Dermatol. 2015. [CrossRef] [PubMed]
147. Sun, H.; Che, Q.M.; Zhao, X.; Pu, X.P. Antifibrotic effects of chronic baicalein administration in a ccl4 liver fibrosis model in rats. Eur. J. Pharmacol. 2010, 631, 53–60. [CrossRef] [PubMed]
148. Prasad, V.; Goldstein, J.A. Us news and world report cancer hospital rankings: Do they reflect measures of research productivity? PLoS ONE 2014, 9, e107803. [CrossRef] [PubMed]
149. Ni, Y.Q.; Zhao, H.R.; Mao, R.; Zhang, H.; Wen, H.; Xiao, L.; Tursun, A.; Bao, Y.X. Clinical epidemiological analysis of 3602 cases of primary liver cancer in xinjiang. Chin. J. Oncol. 2012, 34, 374–377.
150. La Vecchia, C.; Negri, E. A review of epidemiological data on epilepsy, phenobarbital, and risk of liver cancer. Eur. J. Cancer Prev. Off. J. Eur. Cancer Prev. Organ. 2014, 23, 1–7. [CrossRef] [PubMed]
151. Zhang, C.Y.; Huang, T.R.; Yu, J.H.; Zhang, Z.Q.; Li, J.L.; Deng, W.; Ye, S.Y.; Zhou, D.N.; He, Z.F. Epidemiological analysis of primary liver cancer in the early 21st century in guangxi province of china. Chin. J. Cancer 2010, 29, 545–550. [CrossRef] [PubMed]
152. Deugnier, Y.M.; Guyader, D.; Crantock, L.; Lopez, J.M.; Turlin, B.; Yaouanq, J.; Jouanolle, H.; Campion, J.P.; Launois, B.; Halliday, J.W.; et al. Primary liver cancer in genetic hemochromatosis: A clinical, pathological, and pathogenetic study of 54 cases. Gastroenterology 1993, 104, 228–234. [PubMed]
153. Safrany, L.; Balazs, M.; Marton, I. Primary liver cancer. Clinical and pathological study of 74 cases. Orv. Hetil. 1969, 110, 457–463. [PubMed]
154. Zuo, C.; Xia, M.; Wu, Q.; Zhu, H.; Liu, J.; Liu, C. Role of antiviral therapy in reducing recurrence and improving survival in hepatitis b virus-associated hepatocellular carcinoma following curative resection (review). Oncol. Lett. 2015, 9, 527–534. [CrossRef] [PubMed]
155. Llovet, J.M.; Ricci, S.; Mazzaferro, V.; Hilgard, P.; Gane, E.; Blanc, J.F.; de Oliveira, A.C.; Santoro, A.; Raoul, J.L.; Forner, A., et al. Sorafenib in advanced hepatocellular carcinoma. N. Engl. J. Med. 2008, 359, 378–390. [CrossRef] [PubMed]
156. Tan, H.Y.; Wang, N.; Tsao, S.W.; Zhang, Z.; Feng, Y. Suppression of vascular endothelial growth factor via inactivation of eukaryotic elongation factor 2 by alkaloids in coptidis rhizoma in hepatocellular carcinoma. Integr. Cancer Ther. 2014, 13, 425–434. [CrossRef] [PubMed]
157. Wang, N.; Zhu, M.; Wang, X.; Tan, H.Y.; Tsao, S.W.; Feng, Y. Berberine-induced tumor suppressor p53 up-regulation gets involved in the regulatory network of mir-23a in hepatocellular carcinoma. Biochim. Biophys. Acta 2014, 1839, 849–857. [CrossRef] [PubMed]
158. Zhu, M.; Wang, N.; Tsao, S.W.; Yuen, M.F.; Feng, Y.; Wan, T.S.; Man, K.; Feng, Y. Up-regulation of micrornas, mir21 and mir23a in human liver cancer cells treated with coptidis rhizoma aqueous extract. Exp. Ther. Med. 2011, 2, 27–32. [PubMed]
159. Wang, N.; Feng, Y.; Lau, E.P.; Tsang, C.; Ching, Y.; Man, K.; Tong, Y.; Nagamatsu, T.; Su, W.; Tsao, S. F-actin reorganization and inactivation of rho signaling pathway involved in the inhibitory effect of coptidis rhizoma on hepatoma cell migration. Integr. Cancer Ther. 2010, 9, 354–364. [CrossRef] [PubMed]
160. Wang, N.; Feng, Y.; Zhu, M.; Tsang, C.M.; Man, K.; Tong, Y.; Tsao, S.W. Berberine induces autophagic cell death and mitochondrial apoptosis in liver cancer cells: The cellular mechanism. J. Cell. Biochem. 2010, 111, 1426–1436. [CrossRef] [PubMed]
161. Gopalakrishnan, R.; Sundaram, J.; Sattu, K.; Pandi, A.; Thiruvengadam, D. Dietary supplementation of silymarin is associated with decreased cell proliferation, increased apoptosis, and activation of detoxification system in hepatocellular carcinoma. Mol. Cell. Biochem. 2013, 377, 163–176. [CrossRef] [PubMed]
162. Feher, J.; Lengyel, G. Silymarin in the prevention and treatment of liver diseases and primary liver cancer. Curr. Pharm. Biotechnol. 2012, 13, 210–217. [CrossRef] [PubMed]
163. Ramakrishnan, G.; Lo Muzio, L.; Elinos-Baez, C.M.; Jagan, S.; Augustine, T.A.; Kamaraj, S.; Anandakumar, P.; Devaki, T. Silymarin inhibited proliferation and induced apoptosis in hepatic cancer cells. Cell Prolif. 2009, 42, 229–240. [CrossRef] [PubMed]
164. Kang, S.J.; Lee, Y.J.; Kim, B.M.; Kim, Y.J.; Woo, H.D.; Jeon, H.K.; Chung, H.W. Effect of bupleuri radix extracts on the toxicity of 5-fluorouracil in hepg2 hepatoma cells and normal human lymphocytes. Basic Clin. Pharmacol. Toxicol. 2008, 103, 305–313. [CrossRef] [PubMed]
165. Wang, B.F.; Wang, X.J.; Kang, H.F.; Bai, M.H.; Guan, H.T.; Wang, Z.W.; Zan, Y.; Song, L.Q.; Min, W.L.; Lin, S., et al. Saikosaponin-d enhances radiosensitivity of hepatoma cells under hypoxic conditions by inhibiting hypoxia-inducible factor-1alpha. Cell. Physiol. Biochem. Int. J. Exp. Cell. Physiol. Biochem. Pharmacol. 2014, 33, 37–51. [CrossRef] [PubMed]
166. Jia, X.; Dang, S.; Cheng, Y.; Zhang, X.; Li, M.; Li, Y.; Li, S. Effects of saikosaponin-d on syndecan-2, matrix metalloproteinases and tissue inhibitor of metalloproteinases-2 in rats with hepatocellular carcinoma. J. Tradit. Chin. Med. 2012, 32, 415–422. [CrossRef]
167. Rui, W.; Xie, L.; Liu, X.; He, S.; Wu, C.; Zhang, X.; Zhang, L.; Yang, Y. Compound astragalus and salvia miltiorrhiza extract suppresses hepatocellular carcinoma progression by inhibiting fibrosis and pai-1 mrna transcription. J. Ethnopharmacol. 2014, 151, 198–209. [CrossRef] [PubMed]
168. Lee, W.Y.; Cheung, C.C.; Liu, K.W.; Fung, K.P.; Wong, J.; Lai, P.B.; Yeung, J.H. Cytotoxic effects of tanshinones from salvia miltiorrhiza on doxorubicin-resistant human liver cancer cells. J. Nat. Prod. 2010, 73, 854–859. [CrossRef] [PubMed]
169. Lee, W.Y.; Chiu, L.C.; Yeung, J.H. Cytotoxicity of major tanshinones isolated from danshen (salvia miltiorrhiza) on hepg2 cells in relation to glutathione perturbation. Food Chem. Toxicol. An Int. J. Publ. Br. Ind. Biol. Res. Assoc. 2008, 46, 328–338. [CrossRef] [PubMed]
170. Kimura, Y.; Sumiyoshi, M. Anti-tumor and anti-metastatic actions of wogonin isolated from scutellaria baicalensis roots through anti-lymphangiogenesis. Phytomed. Int. J. Phytother. Phytopharmacol. 2013, 20, 328–336. [CrossRef] [PubMed]
171. Ueng, Y.F.; Shyu, C.C.; Liu, T.Y.; Oda, Y.; Lin, Y.L.; Liao, J.F.; Chen, C.F. Protective effects of baicalein and wogonin against benzo[a] pyrene- and aflatoxin b(1)-induced genotoxicities. Biochem. Pharmacol. 2001, 62, 1653–1660. [CrossRef]
172. Tian, J.; Wang, L.; Wang, L.; Ke, X. A wogonin-loaded glycyrrhetinic acid-modified liposome for hepatic targeting with anti-tumor effects. Drug Deliv. 2014, 21, 553–559. [CrossRef] [PubMed]
173. Mao, Y.; Zhang, J.; Hou, L.; Cui, X. The effect of beta-elemene on alpha-tubulin polymerization in human hepatoma hepg2 cells. Chin. J. Cancer Res. 2013, 25, 770–776. [PubMed]
174. Bao, F.; Qiu, J.; Zhang, H. Potential role of beta-elemene on histone h1 in the h22 ascites hepatoma cell line. Mol. Med. Rep. 2012, 6, 185–190. [PubMed]
175. Lau, F.Y.; Chui, C.H.; Gambari, R.; Kok, S.H.; Kan, K.L.; Cheng, G.Y.; Wong, R.S.; Teo, I.T.; Cheng, C.H.; Wan, T.S., et al. Antiproliferative and apoptosis-inducing activity of brucea javanica extract on human carcinoma cells. Int. J. Mol. Med. 2005, 16, 1157–1162. [CrossRef] [PubMed]
176. Yue, Y.; Yang, Y.; Shi, L.; Wang, Z. Suppression of human hepatocellular cancer cell proliferation by brucea javanica oil-loaded liposomes via induction of apoptosis. Arch. Med. Sci. 2015, 11, 856–862. [CrossRef] [PubMed]
177. Li, Q.; Qiu, W.; Zhu, Q.; Zu, Y.; Deng, X.; Zhao, T.; Jiang, C.; Zhang, L. Camptothecin-20(s)-o-[n-(3’alpha, 12’alpha-dihydroxy-24’-carbonyl-5’beta-cholan)] -lysine, a novel camptothecin analogue, induces apoptosis towards hepatocellular carcinoma smmc-7721 cells. Molecules 2011, 16, 7803–7814. [CrossRef] [PubMed]
178. Jayasooriya, R.G.; Choi, Y.H.; Hyun, J.W.; Kim, G.Y. Camptothecin sensitizes human hepatoma hep3b cells to trail-mediated apoptosis via ros-dependent death receptor 5 upregulation with the involvement of mapks. Environ. Toxicol. Pharmacol. 2014, 38, 959–967. [CrossRef] [PubMed]
179. Zhou, L.; Li, X.; Chen, X.; Li, Z.; Liu, X.; Zhou, S.; Zhong, Q.; Yi, T.; Wei, Y.; Zhao, X., et al. In vivo antitumor and antimetastatic activities of camptothecin encapsulated with n-trimethyl chitosan in a preclinical mouse model of liver cancer. Cancer Lett. 2010, 297, 56–64. [CrossRef] [PubMed]
180. Notarbartolo, M.; Poma, P.; Perri, D.; Dusonchet, L.; Cervello, M.; D’Alessandro, N. Antitumor effects of curcumin, alone or in combination with cisplatin or doxorubicin, on human hepatic cancer cells. Analysis of their possible relationship to changes in nf-kb activation levels and in iap gene expression. Cancer Lett. 2005, 224, 53–65. [CrossRef] [PubMed]
181. Wang, W.Z.; Cheng, J.; Luo, J.; Zhuang, S.M. Abrogation of g2/m arrest sensitizes curcumin-resistant hepatoma cells to apoptosis. FEBS Lett. 2008, 582, 2689–2695. [CrossRef] [PubMed]
182. Song, Y.N.; Zhang, G.B.; Zhang, Y.Y.; Su, S.B. Clinical applications of omics technologies on zheng differentiation research in traditional chinese medicine. Evid. Based Complement. Altern. Med. eCAM 2013, 2013, 989618. [CrossRef] [PubMed]
183. Zhang, S.; Shang, H.C. Correlation between traditional chinese medicine syndromes and omics: A literature review. J. Chin. Integr. Med. 2011, 9, 1286–1291. [CrossRef]
184. Kim, J.H.; Lee, S.; Lee, M.Y.; Shin, H.K. Therapeutic effect of soshiho-tang, a traditional herbal formula, on liver fibrosis or cirrhosis in animal models: A systematic review and meta-analysis. J. Ethnopharmacol. 2014, 154, 1–16. [CrossRef] [PubMed]
185. Zhong, G.; Luo, Y.; Xiang, L.; Xie, Y.; Xie, Q.; Li, Y.; Zhang, C. Clinical efficacy study on calming liver and restraining yang formula in treating patients with mild or moderate degree of essential hypertension. China J. Chin. Mater. Med. 2010, 35, 776–781.
186. Liu, W.; Zheng, J.; Xing, R. Clinical significance of a scoring formula of liver injury for the preoperative evaluation of patients with liver cirrhosis. Eur. J. Gastroenterol. Hepatol. 2014, 26, 95–100. [CrossRef] [PubMed]
187. Wu, S.; Ma, X.; Zhou, C.; Zhao, J.; Guo, J.; Xu, W. Effect of fuzhenghuayu compound on hepatocyte expression of nrf2 in a mouse model of hepatic fibrosis. Chin. J. Hepatol. 2014, 22, 609–615.
188. Song, Y.N.; Sun, J.J.; Lu, Y.Y.; Xu, L.M.; Gao, Y.Q.; Zhang, W.; Wang, X.S.; Xue, D.Y.; Zheng, Q.S.; Su, S.B. Therapeutic efficacy of fuzheng-huayu tablet based traditional chinese medicine syndrome differentiation on hepatitis-b-caused cirrhosis: A multicenter double-blind randomized controlled trail. Evid. Based Complement. Altern. Med. eCAM 2013, 2013, 709305. [CrossRef] [PubMed]
189. Wang, R.Q.; Mi, H.M.; Li, H.; Zhao, S.X.; Jia, Y.H.; Nan, Y.M. Modulation of ikkbeta/nf-kappab and tgf-beta1/smad via fuzheng huayu recipe involves in prevention of nutritional steatohepatitis and fibrosis in mice. Iran. J. Basic Med. Sci. 2015, 18, 404–411. [PubMed]
190. Tang, C.L.; Zhou, Z.; Shi, W.Q. Effects of fuzheng huayu capsule on the ratio of tgf-beta1/bmp-7 of chronic viral hepatitis b fibrosis patients of gan-shen insufficiency blood-stasis obstruction syndrome. Chin. J. Integr. Tradit. West. Med. 2012, 32, 20–24.
191. Liu, P.; Hu, Y.Y.; Liu, C.; Xu, L.M.; Liu, C.H.; Sun, K.W.; Hu, D.C.; Yin, Y.K.; Zhou, X.Q.; Wan, M.B., et al. Multicenter clinical study on fuzhenghuayu capsule against liver fibrosis due to chronic hepatitis b. World J. Gastroenterol. WJG 2005, 11, 2892–2899. [CrossRef] [PubMed]
192. Liu, C.; Jiang, C.M.; Liu, C.H.; Liu, P.; Hu, Y.Y. Effect of fuzhenghuayu decoction on vascular endothelial growth factor secretion in hepatic stellate cells. Hepatobiliary Pancreat. Dis. Int. Hbpd Int 2002, 1, 207–210. [PubMed]
193. Sato, A.; Toyoshima, M.; Kondo, A.; Ohta, K.; Sato, H.; Ohsumi, A. [pneumonitis induced by the herbal medicine sho-saiko-to in japan]. Nih. Kyobu Shikkan Gakkai Zasshi 1997, 35, 391–395.
194. Chang, J.S.; Wang, K.C.; Liu, H.W.; Chen, M.C.; Chiang, L.C.; Lin, C.C. Sho-saiko-to (xiao-chai-hu-tang) and crude saikosaponins inhibit hepatitis b virus in a stable hbv-producing cell line. Am. J. Chin. Med. 2007, 35, 341–351. [CrossRef] [PubMed]
195. Tajiri, H.; Kozaiwa, K.; Ozaki, Y.; Miki, K.; Shimuzu, K.; Okada, S. Effect of sho-saiko-to(xiao-chai-hu-tang) on hbeag clearance in children with chronic hepatitis b virus infection and with sustained liver disease. Am. J. Chin. Med. 1991, 19, 121–129. [CrossRef] [PubMed]
196. Deng, G.; Kurtz, R.C.; Vickers, A.; Lau, N.; Yeung, K.S.; Shia, J.; Cassileth, B. A single arm phase ii study of a far-eastern traditional herbal formulation (sho-sai-ko-to or xiao-chai-hu-tang) in chronic hepatitis c patients. J. Ethnopharmacol. 2011, 136, 83–87. [CrossRef] [PubMed]
197. Chen, M.H.; Chen, J.C.; Tsai, C.C.; Wang, W.C.; Chang, D.C.; Lin, C.C.; Hsieh, H.Y. Sho-saiko-to prevents liver fibrosis induced by bile duct ligation in rats. Am. J. Chin. Med. 2004, 32, 195–207. [CrossRef] [PubMed]
198. Chen, M.H.; Chen, J.C.; Tsai, C.C.; Wang, W.C.; Chang, D.C.; Tu, D.G.; Hsieh, H.Y. The role of tgf-beta 1 and cytokines in the modulation of liver fibrosis by sho-saiko-to in rat’s bile duct ligated model. J. Ethnopharmacol. 2005, 97, 7–13. [CrossRef] [PubMed]
199. Oka, H.; Yamamoto, S.; Kuroki, T.; Harihara, S.; Marumo, T.; Kim, S.R.; Monna, T.; Kobayashi, K.; Tango, T. Prospective study of chemoprevention of hepatocellular carcinoma with sho-saiko-to (tj-9). Cancer 1995, 76, 743–749. [CrossRef]
200. Watanabe, S.; Kitade, Y.; Masaki, T.; Nishioka, M.; Satoh, K.; Nishino, H. Effects of lycopene and sho-saiko-to on hepatocarcinogenesis in a rat model of spontaneous liver cancer. Nutr. Cancer 2001, 39, 96–101. [CrossRef] [PubMed]
201. Wang, N.; Feng, Y.; Tan, H.Y.; Cheung, F.; Hong, M.; Lao, L.; Nagamatsu, T. Inhibition of eukaryotic elongation factor-2 confers to tumor suppression by a herbal formulation huanglian-jiedu decoction in human hepatocellular carcinoma. J. Ethnopharmacol. 2015, 164, 309–318. [CrossRef] [PubMed]
202. Sun, J.; Wen, Q.H.; Song, Y.; Li, X.; Jin, J.; Ma, J.S.; Zhou, Q.L. Study on antitumor activities of huanglian jiedu decoction. China J. Chin. Mater. Med. 2006, 31, 1461–1463.
203. Ma, Y.L.; Li, T.; Wang, B.B.; Jia, B.; Chen, B.; Su, J.; Wang, X.B.; Zeng, H. Protection of huanglian jiedu decoction on livers of hyperlipidemia mice. Chin. J. Integr. Tradit. West. Med. 2013, 33, 1107–1111.
204. Jin, J.; Zhang, Y.; Hu, W.X.; Zhang, Z.Y.; Xu, N.N.; Zhou, Q.L. Effects of huanglian jiedu decoction on blood lipid metabolism and its related gene expressions in rats with hyperlipidemia. J. Chin. Integr. Med. 2010, 8, 275–279. [CrossRef]
205. Zhao, Z.J.; Qiu, Q.; Zhang, X.X.; Yang, M.J. Effect of compound biejia ruangan tablet on expressions of connective tissue growth factor mrna and protein in kidney tissue of rats with adriamycin-induced nephropathy. J. Chin. Integr. Med. 2007, 5, 651–655. [CrossRef]
206. Zhou, J.; Chen, X.M.; Liu, S.W.; Fu, B.; Hong, Q.; Wang, S.J. Effects of biejia ruangan tablet-containing serum on matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 expression in cultured renal interstitial fibroblasts. Chin. J. Integr. Med. 2015, 21, 152–156. [CrossRef] [PubMed]
207. Yang, F.R.; Fang, B.W.; Lou, J.S. Effects of fufang biejia ruangan pills on hepatic fibrosis in vivo and in vitro. World J. Gastroenterol. WJG 2013, 19, 5326–5333. [CrossRef] [PubMed]
208. Chen, J.M.; Yang, Y.P.; Chen, D.Y.; Han, J.; Jin, X.Y.; Huang, Z.X.; Xu, C.B.; Shen, Y.M. Efficacy and safety of fufang biejia ruangan tablet in patients with chronic hepatitis b complicated with hepatic fibrosis. Chin. J. Exp. Clin. Virol. 2007, 21, 358–360.
209. Bai, J.X.; Dai, L.; Chen, H.G.; Xu, H.; Yin, R.L.; Han, J.; Yuan, H.L. Study on rational daily administration frequency of fufang biejia ruangan tablet based on integrated serum pharmacologic and pharmacokinetic model. China J. Chin. Mater. Med. 2013, 38, 2394–2398.
210. Allard, T.; Wenner, T.; Greten, H.J.; Efferth, T. Mechanisms of herb-induced nephrotoxicity. Curr. Med. Chem. 2013, 20, 2812–2819. [CrossRef] [PubMed]
211. Vartholomaios, S.; Pitsios, C.; Mikos, N.; Kompoti, E.; Kouridakis, I.S. Allergy to basil, a lamiaceae herb. J. Investig. Allergol. Clin. Immunol. 2007, 17, 348–349. [PubMed]
212. Kheir, M.M.; Wang, Y.; Hua, L.; Hu, J.; Li, L.; Lei, F.; Du, L. Acute toxicity of berberine and its correlation with the blood concentration in mice. Food Chem. Toxicol. An Int. J. Publ. Br. Ind. Biol. Res. Assoc. 2010, 48, 1105–1110. [CrossRef] [PubMed]
213. Kowalewski, Z.; Mrozikiewicz, A.; Bobkiewicz, T.; Drost, K.; Hladon, B. [toxicity of berberine sulfate]. Acta Polon. Pharm. 1975, 32, 113–120.
214. Shin, K.S.; Choi, H.S.; Zhao, T.T.; Suh, K.H.; Kwon, I.H.; Choi, S.O.; Lee, M.K. Neurotoxic effects of berberine on long-term l-dopa administration in 6-hydroxydopamine-lesioned rat model of parkinson’s disease. Arch. Pharm. Res. 2013, 36, 759–767. [CrossRef] [PubMed]
215. Wong, H.B. Singapore kernicterus. Singap. Med. J. 1980, 21, 556–567.
216. Yeung, C.Y.; Lee, F.T.; Wong, H.N. Effect of a popular chinese herb on neonatal bilirubin protein binding. Biol. Neonat. 1990, 58, 98–103. [CrossRef]
217. Chan, E. Displacement of bilirubin from albumin by berberine. Biol. Neonat. 1993, 63, 201–208. [CrossRef]
218. Imanshahidi, M.; Hosseinzadeh, H. Pharmacological and therapeutic effects of berberis vulgaris and its active constituent, berberine. Phytother. Res. PTR 2008, 22, 999–1012. [CrossRef] [PubMed]
219. Conn, J.W.; Rovner, D.R.; Cohen, E.L. Licorice-induced pseudoaldosteronism: Hypertension, hypokalemia, aldosteronopenia, and suppressed plasma renin activity. JAMA J. Am. Med. Assoc. 1968, 205, 492–496. [CrossRef]
220. Somjen, D.; Knoll, E.; Vaya, J.; Stern, N.; Tamir, S. Estrogen-like activity of licorice root constituents: Glabridin and glabrene, in vascular tissues in vitro and in vivo. J. Steroid Biochem. Mol. Biol. 2004, 91, 147–155. [CrossRef] [PubMed]
221. Strandberg, T.E.; Jarvenpaa, A.L.; Vanhanen, H.; McKeigue, P.M. Birth outcome in relation to licorice consumption during pregnancy. Am. J. Epidemiol. 2001, 153, 1085–1088. [CrossRef] [PubMed]
222. Armanini, D.; Bonanni, G.; Palermo, M. Reduction of serum testosterone in men by licorice. N. Engl. J. Med. 1999, 341, 1158. [CrossRef] [PubMed]
223. Isbrucker, R.A.; Burdock, G.A. Risk and safety assessment on the consumption of licorice root (glycyrrhiza sp.), its extract and powder as a food ingredient, with emphasis on the pharmacology and toxicology of glycyrrhizin. Regul. Toxicol. Pharmacol. RTP 2006, 46, 167–192. [CrossRef] [PubMed]
224. Flaig, T.W.; Gustafson, D.L.; Su, L.J.; Zirrolli, J.A.; Crighton, F.; Harrison, G.S.; Pierson, A.S.; Agarwal, R.; Glode, L.M. A phase i and pharmacokinetic study of silybin-phytosome in prostate cancer patients. Investig. New Drugs 2007, 25, 139–146. [CrossRef] [PubMed]
225. Pliskova, M.; Vondracek, J.; Kren, V.; Gazak, R.; Sedmera, P.; Walterova, D.; Psotova, J.; Simanek, V.; Machala, M. Effects of silymarin flavonolignans and synthetic silybin derivatives on estrogen and aryl hydrocarbon receptor activation. Toxicology 2005, 215, 80–89. [CrossRef] [PubMed]
226. El-Shitany, N.A.; Hegazy, S.; El-Desoky, K. Evidences for antiosteoporotic and selective estrogen receptor modulator activity of silymarin compared with ethinylestradiol in ovariectomized rats. Phytomed. Int. J. Phytother. Phytopharmacol. 2010, 17, 116–125. [CrossRef] [PubMed]
227. Loguercio, C.; Festi, D. Silybin and the liver: From basic research to clinical practice. World J. Gastroenterol. WJG 2011, 17, 2288–2301. [CrossRef] [PubMed]
228. Murakami, K.; Okajima, K.; Sakata, K.; Takatsuki, K. A possible mechanism of interstitial pneumonia during interferon therapy with sho-saiko-to. Nih. Kyobu Shikkan Gakkai Zasshi 1995, 33, 389–394.
229. Kim, K.H.; Gam, C.O.; Choi, S.H.; Ku, S.K. Mouse single oral dose toxicity test of bupleuri radix aqueous extracts. Toxicol. Res. 2012, 28, 11–18. [CrossRef] [PubMed]
230. Wang, Z.; Li, H.; Xu, H.; Yue, X.L.; Cheng, X.Q.; Hou, W.J.; Zhang, Y.Y.; Chen, D.F. Beneficial effect of bupleurum polysaccharides on autoimmune disease induced by campylobacter jejuni in balb/c mice. J. Ethnopharmacol. 2009, 124, 481–487. [CrossRef] [PubMed]
231. Wang, R.; Lv, L.; Huang, W.; Huang, Y.; Sun, R. Research on mechanism of energy metabolism disorders of rat’s hepatoxicity induced by saikosaponins. China J. Chin. Mater. Med. 2011, 36, 2557–2561.
232. Huang, W.; Sun, R. Study on hepatotoxicity on rats caused by crude extracts of total saikosaponins and correlation with oxidative damage mechanism. China J. Chin. Mater. Med. 2010, 35, 1745–1749.
233. Kong, X.Y.; Hao, Y.; Wu, T.X.; Xie, Y.M. Adverse drug reactions or adverse events of chaihu injection: A systematic review. J. Chin. Integr. Med. 2010, 8, 1124–1132. [CrossRef]
234. Chen, L.; Zhang, F.; Kong, D.; Zhu, X.; Chen, W.; Wang, A.; Zheng, S. Saikosaponin d disrupts platelet-derived growth factor-beta receptor/p38 pathway leading to mitochondrial apoptosis in human lo2 hepatocyte cells: A potential mechanism of hepatotoxicity. Chem. Biol. Interact. 2013, 206, 76–82. [CrossRef] [PubMed]
235. Hu, Z.; Yang, X.; Ho, P.C.; Chan, S.Y.; Heng, P.W.; Chan, E.; Duan, W.; Koh, H.L.; Zhou, S. Herb-drug interactions: A literature review. Drugs 2005, 65, 1239–1282. [CrossRef] [PubMed]
236. Chan, T.Y. Interaction between warfarin and danshen (salvia miltiorrhiza). Ann. Pharmacother. 2001, 35, 501–504. [CrossRef] [PubMed]
237. Fugh-Berman, A. Herb-drug interactions. Lancet 2000, 355, 134–138. [CrossRef]
238. Yang, W.; Yu, X.; He, P.; Hao, W.; Li, Y. Experimental study on anaphylactoid reactions of guinea pig induced by danshen injection and its components. China J. Chin. Mater. Med. 2012, 37, 1894–1897.
239. Wang, J.Y.; Lee, C.Y.; Pan, P.J.; Chang, W.C.; Chiu, J.H.; Chen, W.S.; Shyr, Y.M. Herb-induced autoimmune-like hepatitis in c57bl/6j mice. Liv. Int. Off. J. Int. Assoc. Study Liv. 2014, 34, 583–593. [CrossRef] [PubMed]
240. Itoh, S.; Marutani, K.; Nishijima, T.; Matsuo, S.; Itabashi, M. Liver injuries induced by herbal medicine, syo-saiko-to (xiao-chai-hu-tang). Dig. Dis. Sci. 1995, 40, 1845–1848. [CrossRef] [PubMed]
241. Hsu, L.M.; Huang, Y.S.; Tsay, S.H.; Chang, F.Y.; Lee, S.D. Acute hepatitis induced by chinese hepatoprotective herb, xiao-chai-hu-tang. J. Chin. Med. Assoc. JCMA 2006, 69, 86–88. [CrossRef]
242. Qi, Q.; Peng, J.; Liu, W.; You, Q.; Yang, Y.; Lu, N.; Wang, G.; Guo, Q. Toxicological studies of wogonin in experimental animals. Phytother. Res. PTR 2009, 23, 417–422. [CrossRef] [PubMed]
243. Deng, L.; Song, D.; Guo, J.; Wang, Y. Study on ingredients of scutellaria radix extract penetrable through placental barrier of pregnant rat. China J. Chin. Mater. Med. 2012, 37, 327–330.